FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Experimental treatment pushed by ALS patients gets day before FDA, but agency unconvinced it worksThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrigโs disease.
โMy military service increases my chance of developing ALS:โ Veteran works to find a cureVeterans more likely to develop ALS, studies show, especially those with family history
NIH to fund unproven ALS drugs under patient-backed lawThe U.S. government will soon spend $25 million to help patients access experimental drugs for the incurable illness known as Lou Gehrig's disease.
FDA panel backs much-debated ALS drug in rare, 2nd reviewA panel of federal health advisers has voted to recommend approval for an experimental drug to treat Lou Gehrigโs disease.
FDA panel narrowly sides against experimental ALS drugFederal health advisers have narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrigโs disease.
FDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrigโs disease.
Pressured by patients, FDA reviews ALS drug with modest dataThe Food and Drug Administration meets next week to review a closely watched drug for ALS, or Lou Gehrigโs disease, following months of lobbying by patient groups and congressional lawmakers.